Impact of renal impairment on pharmacokinetics, safety, and tolerability of funobactam, combined with imipenem and cilastatin
Open Access
- 7 October 2026
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (10)
Abstract
A phase 1, open-label study was conducted to investigate the effect of renal impairment (RI) on pharmacokinetics (PK) and safety of funobactam plus imipenem/cilastatin. Participants were enrolled and assigned to one of five cohorts based on renal function category: normal renal function, mild RI, moderate RI, severe RI, and end-stage renal disease (ESRD) requiring hemodialysis (HD). Participants received a single-dose of funobactam with imipenem and cilastatin by intravenous infusion administered over 60 min. Serial blood and urine samples were collected for non-compartmental PK analysis. Compared to participants with normal renal function, the geometric mean ratio (90% confidence interval) of plasma area under the curve (AUC0-∞) for funobactam, imipenem, and cilastatin increased with RI from mild (1.32 [1.04, 1.66], 1.37 [1.04, 1.79], and 1.27 [0.90, 1.78], respectively) to ESRD requiring HD (9.58 [7.59, 12.10], 2.69 [2.06, 3.52], and 15.15 [10.8, 21.3], respectively). The renal clearance for funobactam, imipenem, and cilastatin decreased progressively from normal renal function (3.93 ± 1.12 L/h, 4.95 ± 2.40 L/h, and 6.98 ± 2.75 L/h, respectively) to severe RI (0.94 ± 0.37 L/h, 1.16 ± 0.34 L/h, and 1.70 ± 0.60 L/h, respectively). Plasma clearance of funobactam, imipenem, and cilastatin correlated (r ≥0.93) with creatinine clearance and the estimated glomerular filtration rate. The treatment was well tolerated, with no deaths, severe adverse events, or discontinuation due to adverse events. Dosage adjustments of funobactam, imipenem, and cilastatin will be needed in patients with renal impairment or ESRD requiring HD. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04787562 .Keywords
Funding Information
- Evopoint Biosciences USA, Inc. (Funobactam Renal Impairment Study)
This publication has 13 references indexed in Scilit:
- Plasma and intrapulmonary pharmacokinetics of funobactam, a novel diazabicyclooctane β-lactamase inhibitor, administered in combination with imipenem/cilastatin in healthy subjectsAntimicrobial Agents and Chemotherapy, 2026
- Imipenem/funobactam (formerly XNW4107) in vivo pharmacodynamics against serine carbapenemase-producing Gram-negative bacteria: a novel modelling approach for time-dependent killingJournal of Antimicrobial Chemotherapy, 2023
- In vitro and in vivo activities of a novel β-lactamase inhibitor combination imipenem/XNW4107 against recent clinical Gram-negative bacilli from ChinaJournal of Global Antimicrobial Resistance, 2022
- Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatinBritish Journal of Clinical Pharmacology, 2020
- Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy ParticipantsAntimicrobial Agents and Chemotherapy, 2018
- When to Conduct a Renal Impairment Study During Drug Development: US Food and Drug Administration PerspectiveClinical Pharmacology & Therapeutics, 2009
- Drug Development Perspective on Pharmacokinetic Studies of New Drugs in Patients With Renal ImpairmentClinical Pharmacology & Therapeutics, 2009
- Pharmacokinetics and tolerance after repeated doses of imipenem/cilastatin in patients with severe renal failureJournal of Antimicrobial Chemotherapy, 1986
- Imipenem/cilastatin: Pharmacokinetic profile in renal insufficiencyThe American Journal of Medicine, 1985
- Multiple-dose pharmacokinetics of imipenem-cilastatinAntimicrobial Agents and Chemotherapy, 1984